AYTU BIOPHARMA, INC AYTU
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2017-10-20
AYTU BIOPHARMA, INC statistics & valuation
Market cap$23.3M
P / S0.4×
P / B1.2×
Net margin-20.4%
Return on equity-71.5%
FCF margin-3.3%
Net cash$20.1M
Enterprise value USD$3.2M
Return on capital-12.8%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 69.0% | 75.3% | 62.0% | 54.1% | 44.5% | 70.0% | — | — | — | — |
| Operating margin | -11.8% | -2.4% | -15.9% | -113.7% | -89.7% | -76.5% | -230.1% | -538.2% | -624.7% | -847.0% |
| Net margin | -20.4% | -24.3% | -15.9% | -112.5% | -88.8% | -49.3% | -370.6% | -278.3% | -698.7% | -1099.7% |
| FCF margin | -3.3% | -2.6% | — | — | — | -102.7% | -189.8% | -437.6% | -432.7% | -425.8% |
| Return on assets | -10.9% | -13.4% | -12.5% | -79.0% | -21.9% | -8.9% | -78.1% | -48.4% | -150.1% | -115.8% |
| Return on equity | -71.5% | -57.2% | -43.3% | -245.5% | -42.4% | -14.3% | -382.8% | -75.9% | -562.7% | -279.4% |
| Debt / equity | 0.57× | 0.39× | 0.38× | 0.34× | — | — | 0.00× | 0.00× | — | — |
| Current ratio | 1.26 | 0.99 | 1.06 | 0.93 | 0.96 | 2.62 | 2.87 | 2.79 | 0.84 | 1.00 |
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.